Exact Sciences (EXAS) to Release Earnings on Wednesday

Key Points

• Exact Sciences is expected to release its Q2 2025 earnings results on August 6th, with analysts predicting a loss of ($0.04) per share and revenue of $774.43 million.
• The company reported a revenue increase of 10.9% in its previous quarter compared to the same period last year, beating revenue estimates of $688.58 million.
• Exact Sciences' stock price opened at $47.54, and it currently holds an average rating of "Moderate Buy" from analysts, with a target price of $70.50.

Exact Sciences (NASDAQ:EXAS - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect Exact Sciences to post earnings of ($0.04) per share and revenue of $774.43 million for the quarter. Exact Sciences has set its FY 2025 guidance at EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.16. The firm had revenue of $706.79 million for the quarter, compared to the consensus estimate of $688.58 million. Exact Sciences had a negative return on equity of 3.75% and a negative net margin of 36.06%. The company's revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.60) EPS. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS traded down $0.74 during midday trading on Wednesday, hitting $46.80. The stock had a trading volume of 1,877,084 shares, compared to its average volume of 2,070,840. The company has a market capitalization of $8.83 billion, a P/E ratio of -8.49, a price-to-earnings-growth ratio of 10.15 and a beta of 0.95. Exact Sciences has a fifty-two week low of $39.97 and a fifty-two week high of $72.83. The company's 50-day moving average price is $53.13 and its 200-day moving average price is $50.44. The company has a quick ratio of 2.38, a current ratio of 2.73 and a debt-to-equity ratio of 0.97.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on EXAS shares. Robert W. Baird lifted their price target on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Guggenheim restated a "buy" rating and set a $60.00 price objective on shares of Exact Sciences in a research note on Friday, April 11th. Royal Bank Of Canada increased their price objective on shares of Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Mizuho started coverage on Exact Sciences in a research note on Thursday, April 10th. They issued an "outperform" rating and a $60.00 target price on the stock. Finally, Evercore ISI increased their target price on Exact Sciences from $66.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Exact Sciences has a consensus rating of "Moderate Buy" and an average price target of $70.50.

Insider Buying and Selling at Exact Sciences

In related news, Director Katherine S. Zanotti sold 3,207 shares of Exact Sciences stock in a transaction on Friday, June 13th. The stock was sold at an average price of $53.20, for a total transaction of $170,612.40. Following the completion of the sale, the director owned 72,759 shares of the company's stock, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Exact Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of EXAS. Integrated Wealth Concepts LLC bought a new stake in shares of Exact Sciences in the 1st quarter valued at about $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Exact Sciences by 11.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company's stock valued at $921,000 after buying an additional 2,231 shares in the last quarter. Great Lakes Advisors LLC boosted its position in Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company's stock worth $215,000 after purchasing an additional 178 shares during the period. Finally, Focus Partners Wealth grew its position in shares of Exact Sciences by 12.6% during the 1st quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company's stock valued at $933,000 after buying an additional 2,413 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.